|
NexMed Confirms FDA Acceptance Of NDA For Erectle Dysfunction Product |
|
Written by Administrator
|
|
Wednesday, 21 November 2007 |
|
NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, announced that the New Drug Application (NDA) filed by the Company for its erectile dysfunction (ED) product, a topically applied alprostadil cream, was accepted for review by the U.S. Food and Drug Administration (FDA).
Read more at: . |
|
Last Updated ( Saturday, 05 January 2008 )
|
News 
